胆汁酸相关非酒精性脂肪性肝病发病机制及其药物治疗的研究进展

张敏; 黄明星; 郭列军

doi:10.3969/j.issn.1001-5256.2017.06.034

胆汁酸相关非酒精性脂肪性肝病发病机制及其药物治疗的研究进展

DOI: 10.3969/j.issn.1001-5256.2017.06.034

1. 解放军第三〇二医院青少年肝病诊疗与研究中心
2. 中山大学附属第五医院
3. 罗格斯大学环境与职业健康研究所

详细信息

中图分类号: R575.5
计量
- 文章访问数: 2284
- HTML全文浏览量: 27
- PDF下载量: 515
- 被引次数: 0
出版历程
- 收稿日期: 2017-01-04
- 出版日期: 2017-06-20

Research advances in the pathogenesis of bile acid-related non-alcoholic fatty liver disease and related pharmacotherapy

Treatment and Research Center of Children's Liver Disease, 302 Hospital of PLA

摘要

摘要: 非酒精性脂肪性肝病发病率增加,已成为一个新的全球卫生问题。非酒精性脂肪性肝炎为其进展形式,预后不良,亟待寻找预防疾病进展并进行治疗的方法。胆汁酸作为一个重要的代谢物和信号分子,能够在肝内和肝外组织调节脂类和碳水化合物代谢以及能量平衡。胆汁酸与其受体如法尼酯X受体和Takeda G蛋白偶联受体5、胆汁酸转运蛋白、肠道菌群等相互作用,可以在不同层面参与非酒精性脂肪性肝病/非酒精性脂肪性肝炎的发病机理。总结了胆汁酸相关非酒精性脂肪性肝病发病机制及其药物治疗的研究进展。
- 脂肪肝 /
- 胆酸类 /
- 受体,G-蛋白偶联 /
- 综述
Abstract: Non-alcoholic fatty liver disease (NAFLD) has become a new health issue in the world due to its increasing incidence rate, and in particular, nonalcoholic steatohepatitis is progressive and has poor prognosis. Therefore, there is an urgent need to search for the methods for the prevention of disease progression and treatment. Bile acid, as an important metabolite and signal molecule, can adjust the metabolism of lipids and carbohydrates and energy balance inside and outside the liver. Bile acid interacts with its receptors, such as the farnesoid X receptor and Takeda G-protein coupled receptor 5, bile acid transporter, and gut microbiota and is involved in the pathogenesis of NAFLD and nonalcoholic steatohepatitis at different levels. This article summarizes the research advances in the pathogenesis of bile acid-related NAFLD and related pharmacotherapy.
- fatty liver /
- cholic acids /
- receptors, G-protein-coupled /
- review

HTML全文

参考文献(53)

[1]SATAPATHY SK, SABTAL AJ.Epidemiology and natural history of nonalcoholic fatty liver disease[J].Semin Liver Dis, 2015, 35 (3) :221-235.

[2]European Association for the Study of the Liver (EASL) , European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) .EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease[J].Obes Facts, 2016, 9 (2) :65-90.

[3]CHIANG JY.Bile acid metabolism and signaling[J].Compr Physiol, 2013, 3 (3) :1191-1212.

[4]LI Y, JADHAV K, ZHANG Y.Bile acid receptors in non-alcoholic fatty liver disease[J].Biochem Pharmacol, 2013, 86 (11) :1517-1524.

[5]YUAN L, BAMBHA K.Bile acid receptors and nonalcoholic fatty liver disease[J].World J Hepatol, 2015, 7 (28) :2811-2818.

[6]DAWSON PA, KARPEN SJ.Intestinal transport and metabolism of bile acids[J].J Lipid Res, 2015, 56 (6) :1085-1099.

[7]RIDLON JM, BAJAJ JS.The human gut sterol biome:bile acid microbiome endocrine aspects and therapeutics[J].Acta Pharm Sin B, 2015, 5 (2) :99-105.

[8]VERNON G, BARANOVA A, YOUNOSSI ZM.Systematic review:the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults[J].Aliment Pharmacol Ther, 2011, 34 (3) :274-285.

[9]FAN JG, ZHU J, LI XJ, et al.Epidemiological survey of prevalence of fatty liver and its risk factors in a general adult population of Shanghai[J].Chin J Hepatol, 2005, 13 (2) :83-88. (in Chinese) 范建高, 朱军, 李新建, 等.上海市成人脂肪肝患病率及其危险因素流行病学调查[J].中华肝脏病杂志, 2005, 13 (2) :83-88.

[10]GERBER L, OTGONSUREN M, MISHRA A, et al.Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity:a population-based study[J].Aliment Pharmacol Ther, 2012, 36 (8) :772-781.

[11]LIU YL, PATMAN GL, LEATHART JB, et al.Carriage of the PNPLA3 rs738409 C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma[J].J Hepatol, 2014, 61 (1) :75-81.

[12]ANSTEE QM, DAY CP.The genetics of nonalcoholic fatty liver disease:spotlight on PNPLA3 and TM6SF2[J].Semin Liver Dis, 2015, 35 (3) :270-290.

[13]TILG H, MOSCHEN AR.Evolution of inflammation in nonalcoholic fatty liver disease:the multiple parallel hits hypothesis[J].Hepatology, 2010, 52 (5) :1836-1846.

[14]PIZARRO M, BALASUBRAMANIYAN N, SOLIS N, et al.Bile secretory function in the obese Zucker rat:evidence of cholestasis and altered canalicular transport function[J].Gut, 2004, 53 (12) :1837-1843.

[15]BOYER JL.Bile formation and secretion[J].Compr Physiol, 2013, 3 (3) :1035-1078.

[16]COPPLE BL, LI T.Pharmacology of bile acid receptors:Evolution of bile acids from simple detergents to complex signaling molecules[J].Pharmacol Res, 2016, 104 (1) :9-21.

[17]KONG B, WANG L, CHIANG JY, et al.Mechanism of TissueSpecific Farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice[J].Hepatology, 2012, 56 (3) :1034-1043.

[18]ZHANG Y, LEE FY, BARRERA G, et al.Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice[J].Proc Natl Acad Sci U S A, 2006, 103 (4) :1006-1011.

[19] STAYROOK KR, BRAMLETT KS, SAVKUR RS, et al.Regulation of carbohydrate metabolism by the farnesoid X receptor[J].Endocrinology, 2005, 146 (3) :984-991.

[20]SINAL CJ, TOHKIN M, MIYATA M, et al.Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis[J].Cell, 2000, 102 (6) :731-744.

[21]WATANABE M, HOUTEN SM, WANG L, et al.Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c[J].J Clin Invest, 2004, 113 (10) :1408-1418.

[22]FUCHS CD, TRAUSSNIGG SA, TRAUNER M.Nuclear receptor modulation for the treatment of nonalcoholic fatty liver disease[J].Semin Liver Dis, 2016, 36 (1) :69-86.

[23]MAZUY C, HELLEBOID A, STAELS B, et al.Nuclear bile acid signaling through the farnesoid X receptor[J].Cell Mol Life Sci, 2015, 72 (9) :1631-1650.

[24]CHAO F, GONG W, ZHENG Y, et al.Upregulation of scavenger receptor class B type I expression by activation of FXR in hepatocyte[J].Atherosclerosis, 2010, 213 (2) :443-448.

[25]CARIOU B, CHETIVEAUX M, ZAIR Y, et al.Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults[J].Nutr Metab, 2011, 8 (1) :48.

[26]STAYROOK KR, BRAMLETT KS, SAVKUR RS, et al.Regulation of carbohydrate metabolism by the farnesoid X receptor[J].Endocrinology, 2005, 146 (3) :984-991.

[27]PRAWITT J, ABDELKARIM M, STROEVE JH, et al.Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity[J].Diabetes, 2011, 60 (7) :1861-1871.

[28]ZHAN L, LIU HX, FANG Y, et al.Genome-wide binding and transcriptome analysis of human farnesoid X receptor in primary human hepatocytes[J].PLo S One, 2014, 9 (9) :e105930.

[29]DUBOC H, TACHE Y, HOFMANN AF.The bile acid TGR5 membrane receptor:from basic research to clinical application[J].Dig Liver Dis, 2014, 46 (4) :302-312.

[30]BROEDERS EP, NASCIMENTO EB, HAVEKES B, et al.The bile acid chenodeoxycholic acid increases human brown adipose tissue activity[J].Cell Metab, 2015, 22 (3) :418-426.

[31]THOMAS C, GIOIELLO A, NORIEGA L, et al.TGR5-mediated bile acid sensing controls glucose homeostasis[J].Cell Metab, 2009, 10 (3) :167-177.

[32]KUMAR DP, ASGHARPOUR A, MIRSHAHI F, et al.Activation of transmembrane bile acid receptor TGR5 modulates pancreatic islet alpha cells to promote glucose homeostasis[J].J Biol Chem, 2016, 291 (13) :6626-6640.

[33]PERINO A, SCHOONJANS K.TGR5 and immunometabolism:insights from physiology and pharmacology[J].Trends Pharmacol Sci, 2015, 36 (12) :847-857.

[34]GEIER A, DIETRICH CG, GROTE T, et al.Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat[J].J Hepatol, 2005, 43 (6) :1021-1030.

[35]MACALUSO FS, MAIDA M, PETTA S.Genetic background in nonalcoholic fatty liver disease:a comprehensive review[J].World J Gastroenterol, 2015, 21 (39) :11088-11111.

[36]IWATA R, BAUR K, STIEGER B, et al.A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in nonalcoholic fatty liver disease[J].Clin Sci, 2011, 120 (7) :287-296.

[37]JIANG C, XIE C, LV Y, et al.Intestine selective farnesoid X receptor inhibition improves obesity related metabolic dysfunction[J].Nat Commun, 2015, 6:10166.

[38]SAYIN SI, WAHLSTROM A, FELIN J, et al.Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist[J].Cell Metab, 2013, 17 (2) :225-235.

[39]VAN BEST N, JANSEN PL, RENSEN SS.The gut microbiota of nonalcoholic fatty liver disease:current methods and their interpretation[J].Hepatol Int, 2015, 9 (3) :406-415.

[40]VILAR-GOMEZ E, MARTINEZ-PEREZ Y, CALZADILLABERTOT L, et al.Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis[J].Gastroenterology, 2015, 149 (2) :367-378.

[41]AITHAL GP, THOMAS JA, KAYE PV, et al.Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis[J].Gastroenterology, 2008, 135 (4) :1176-1184.

[42]LAVINE JE, SCHWIMMER JB, VAN NATTA ML, et al.Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents:the TONIC randomized controlled trial[J].JAMA, 2011, 305 (16) :1659-1668.

[43]DONGIOVANNI P, PETTA S, MANNISTO V, et al.Statin use and nonalcoholic steatohepatitis in at risk individuals[J].J Hepatol, 2015, 63 (3) :705-712.

[44]ALI AH, CAREY EJ, LINDOR KD.Recent advances in the development of farnesoid X receptor agonists[J].Ann Transl Med, 2015, 3 (1) :5.

[45]MUDALIAR S, HENRY RR, SANYAL AJ, et al.Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease[J].Gastroenterology, 2013, 145 (3) :574-582.

[46]NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al.Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, non-alcoholic steatohepatitis (FLINT) :a multicentre, randomised, placebocontrolled trial[J].Lancet, 2015, 385 (9972) :956-965.

[47]CORREIA JC, MASSART J, de BOER JF, et al.Bioenergetic cues shift FXR splicing towards FXRalpha2 to modulate hepatic lipolysis and fatty acid metabolism[J].Mol Metab, 2015, 4 (12) :891-902.

[48]PELLICCIARI R, GIOIELLO A, MACCHIARULO A, et al.Discovery of6alpha-ethyl-23 (S) -methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity[J].J Med Chem, 2009, 52 (24) :7958-7961.

[49]MCMAHAN RH, WANG XX, CHENG LL, et al.Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease[J].J Biol Chem, 2013, 288 (17) :11761-11770.

[50]HODGE RJ, NUNEZ DJ.The therapeutic potential of TGR5 agonists.Hope or hype?[J].Diabetes Obes Metab, 2016, 18 (5) :439-443.

[51]BERAZA N, OFNER-ZIEGENFUSS L, EHEDEGO H, et al.Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis[J].Gut, 2011, 60 (3) :387-396.

[52]RAO A, KOSTERS A, MELLS J, et al.Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice[J].Sci Transl Med, 2016, 8 (357) :357ra122.

[53]BAARS A, OOSTING A, KNOL J, et al.The gut microbiota as a therapeutic target in IBD and metabolic disease:a role for the bile acid receptors FXR and TGR5[J].Microorganisms, 2015, 3 (4) :641-666.

施引文献

资源附件(0)

访问统计